دورية أكاديمية
Lysophosphatidic Acid Signaling and microRNAs: New Roles in Various Cancers.
| العنوان: | Lysophosphatidic Acid Signaling and microRNAs: New Roles in Various Cancers. |
|---|---|
| المؤلفون: | Rafiyan M; School of Medicine, Kashan University of Medical Sciences, Kashan, Iran.; Student Research Committee, Kashan University of Medical Sciences, Kashan, Iran., Abadi MHJN; Department of Medical Biotechnology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran., Zadeh SST; School of Medicine, Tehran University of Medical Sciences, Tehran, Iran., Hamblin MR; Laser Research Centre, Faculty of Health Science, University of Johannesburg, Doornfontein, South Africa., Mousavi M; Department of Anatomy, Faculty of Medicine, Semnan University of Medical Sciences, Semnan, Iran., Mirzaei H; Center for Biochemistry and Nutrition in Metabolic Diseases, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, Iran. |
| المصدر: | Frontiers in oncology [Front Oncol] 2022 Jun 23; Vol. 12, pp. 917471. Date of Electronic Publication: 2022 Jun 23 (Print Publication: 2022). |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مستخلص: | A wide range of microRNAs (miRNAs) are coded for in the human genome and contribute to the regulation of gene expression. MiRNAs are able to degrade mRNAs and/or prevent the RNA transcript from being translated through complementary binding of the miRNA seed region (nucleotide 2-8) to the 3'-untranslated regions of many mRNAs. Although miRNAs are involved in almost all processes of normal human cells, they are also involved in the abnormal functions of cancer cells. MiRNAs can play dual regulatory roles in cancer, acting either as tumor suppressors or as tumor promoters, depending on the target, tumor type, and stage. In the current review, we discuss the present status of miRNA modulation in the setting of lysophosphatidic acid (LPA) signaling. LPA is produced from lysophosphatidylcholine by the enzyme autotaxin and signals via a range of G protein-coupled receptors to affect cellular processes, which ultimately causes changes in cell morphology, survival, proliferation, differentiation, migration, and adhesion. Several studies have identified miRNAs that are over-expressed in response to stimulation by LPA, but their functional roles have not yet been fully clarified. Since RNA-based treatments hold tremendous promise in the area of personalized medicne, many efforts have been made to bring miRNAs into clinical trials, and this field is evolving at an increasing pace. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Rafiyan, Abadi, Zadeh, Hamblin, Mousavi and Mirzaei.) |
| References: | J Virol. 2003 Sep;77(17):9669-84. (PMID: 12915579) Br J Pharmacol. 2010 Sep;161(2):241-70. (PMID: 20735414) Int J Biol Sci. 2017 Nov 1;13(11):1387-1397. (PMID: 29209143) Am J Physiol Gastrointest Liver Physiol. 2010 Nov;299(5):G1128-38. (PMID: 20724530) Mol Ther Nucleic Acids. 2021 Oct 08;26:892-926. (PMID: 34760336) Nat Cell Biol. 2008 Dec;10(12):1470-6. (PMID: 19011622) Mol Cancer. 2012 Sep 20;11:71. (PMID: 22992343) Proc Natl Acad Sci U S A. 2010 Mar 23;107(12):5681-6. (PMID: 20176930) Curr Genomics. 2010 Nov;11(7):537-61. (PMID: 21532838) Physiol Rev. 2013 Jan;93(1):69-106. (PMID: 23303906) Cancers (Basel). 2020 May 10;12(5):. (PMID: 32397679) Braz J Med Biol Res. 2017 Apr 20;50(5):e6359. (PMID: 28443990) Biochim Biophys Acta. 2008 Sep;1781(9):513-8. (PMID: 18621144) Biosci Rep. 2020 Aug 28;40(8):. (PMID: 32766727) PLoS One. 2015 Sep 29;10(9):e0139489. (PMID: 26418018) J Clin Invest. 2001 Jun;107(12):1599-606. (PMID: 11413168) Radiographics. 1997 Sep-Oct;17(5):1205-31. (PMID: 9308111) J Biochem. 2010 Jul;148(1):13-24. (PMID: 20495010) Oncogene. 2005 Mar 3;24(10):1774-87. (PMID: 15674352) PLoS One. 2014 May 14;9(5):e97771. (PMID: 24828490) Free Radic Biol Med. 2011 Nov 15;51(10):1903-9. (PMID: 21925592) J Cell Physiol. 2019 Dec;234(12):22331-22342. (PMID: 31140597) Arch Pathol Lab Med. 2013 Feb;137(2):289-94. (PMID: 23368874) Arch Biochem Biophys. 2013 Jul 15;535(2):128-35. (PMID: 23578572) Signal Transduct Target Ther. 2021 Feb 1;6(1):45. (PMID: 33526777) Cancer. 1995 May 1;75(9):2209-13. (PMID: 7712429) Arch Int Pharmacodyn Ther. 1980 May;245(1):74-83. (PMID: 6902643) PLoS One. 2012;7(3):e33778. (PMID: 22457788) Oncotarget. 2015 Aug 21;6(24):20604-20. (PMID: 26098771) Arzneimittelforschung. 1985;35(3):287-92. (PMID: 3846454) Cancer Res. 2013 Jun 15;73(12):3625-37. (PMID: 23536558) Nat Rev Drug Discov. 2017 Mar;16(3):203-222. (PMID: 28209991) Int J Gynecol Cancer. 2015 Jan;25(1):18-23. (PMID: 25398018) J Am Soc Nephrol. 2012 Dec;23(12):2012-23. (PMID: 23160513) Int J Breast Cancer. 2012;2012:654698. (PMID: 22295247) Biol Reprod. 2015 Nov;93(5):123. (PMID: 26447143) J Immunol. 2010 May 1;184(9):5186-92. (PMID: 20357254) Mol Ther Oncolytics. 2021 Dec 22;24:262-287. (PMID: 35071748) Nat Genet. 2008 Mar;40(3):329-34. (PMID: 18297070) J Biol Chem. 2002 Sep 13;277(37):34254-63. (PMID: 12063250) Cell Mol Biol Lett. 2022 Feb 14;27(1):14. (PMID: 35164678) Mol Cancer Ther. 2011 Aug;10(8):1337-45. (PMID: 21666078) Cancer Cell Int. 2015 Apr 02;15:38. (PMID: 25960691) Prog Lipid Res. 2015 Apr;58:51-75. (PMID: 25704399) Nat Genet. 2006 Jun;38 Suppl:S8-13. (PMID: 16736023) Nat Genet. 2005 Jul;37(7):766-70. (PMID: 15965474) Annu Rev Genet. 2015;49:213-42. (PMID: 26473382) Front Cell Dev Biol. 2021 Sep 27;9:716462. (PMID: 34646821) Cell. 1993 Dec 3;75(5):843-54. (PMID: 8252621) Biochem Biophys Res Commun. 2011 Dec 9;416(1-2):31-8. (PMID: 22093834) Mol Oncol. 2015 Jun;9(6):1106-19. (PMID: 25732226) PLoS One. 2015 Sep 29;10(9):e0139094. (PMID: 26418031) Circ Res. 2008 Sep 12;103(6):662-70. (PMID: 18703779) Brain Behav Immun. 2009 Feb;23(2):176-83. (PMID: 18550328) Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13384-9. (PMID: 11087877) PLoS Pathog. 2013;9(9):e1003584. (PMID: 24039573) Nature. 2005 May 5;435(7038):104-8. (PMID: 15875025) Cancer Res. 1980 Sep;40(9):3357-60. (PMID: 7427948) J Am Soc Nephrol. 2007 Dec;18(12):3110-8. (PMID: 18003779) Front Endocrinol (Lausanne). 2018 Aug 03;9:402. (PMID: 30123182) J Lipid Res. 2002 Dec;43(12):2049-55. (PMID: 12454265) Nat Med. 2006 Aug;12(8):939-44. (PMID: 16862152) J Cell Biochem. 2020 Feb;121(2):1911-1922. (PMID: 31746031) FASEB J. 2014 Jun;28(6):2655-66. (PMID: 24599971) Cancer Lett. 2018 Sep 28;432:84-92. (PMID: 29859298) J Biol Chem. 2006 Sep 1;281(35):25822-30. (PMID: 16829511) Front Bioeng Biotechnol. 2021 Jan 18;8:619583. (PMID: 33537295) J Mol Med (Berl). 2009 Nov;87(11):1053-60. (PMID: 19705082) Prog Lipid Res. 2007 Mar;46(2):145-60. (PMID: 17459484) Cell. 1989 Oct 6;59(1):45-54. (PMID: 2551506) Mol Cancer Res. 2011 Dec;9(12):1732-45. (PMID: 22024689) Med Sci Monit. 2020 Jan 06;26:e919820. (PMID: 31902939) J Biol Chem. 2010 Apr 23;285(17):12536-42. (PMID: 20164172) Biochimie. 2010 Jun;92(6):698-706. (PMID: 20417246) Biochem Biophys Res Commun. 1981 Mar 31;99(2):391-8. (PMID: 6909028) JAMA. 2019 Jan 22;321(3):288-300. (PMID: 30667505) CNS Neurol Disord Drug Targets. 2013 May 1;12(3):381-91. (PMID: 23469855) Cancer Cell. 2009 Jun 2;15(6):539-50. (PMID: 19477432) J Virol. 2007 Jun;81(12):6573-83. (PMID: 17409151) J Dermatol Sci. 2015 Jun;78(3):197-205. (PMID: 25828854) Cell Physiol Biochem. 2016;40(5):1117-1128. (PMID: 27960154) Lancet. 2020 Aug 29;396(10251):635-648. (PMID: 32861308) Med Oncol. 2011 Sep;28(3):796-803. (PMID: 20401641) Int J Mol Sci. 2019 Jun 11;20(11):. (PMID: 31212704) Dig Dis Sci. 2013 Dec;58(12):3524-33. (PMID: 24061591) Nat Immunol. 2008 Apr;9(4):415-23. (PMID: 18327261) Cancer. 1984 Feb 1;53(3 Suppl):630-43. (PMID: 6692266) FEBS Lett. 2002 Jul 17;523(1-3):187-92. (PMID: 12123830) Int J Genomics. 2014;2014:970607. (PMID: 25180174) Biochim Biophys Acta. 2016 Sep;1862(9):1617-27. (PMID: 27264337) Biomed Res Int. 2014;2014:687826. (PMID: 24995320) BMC Gastroenterol. 2021 Feb 10;21(1):58. (PMID: 33568105) Cell Cycle. 2009 Nov 15;8(22):3695-701. (PMID: 19855166) Nat Rev Cancer. 2003 Aug;3(8):582-91. (PMID: 12894246) World J Gastroenterol. 2016 Feb 28;22(8):2503-11. (PMID: 26937138) Reprod Sci. 2019 Jan;26(1):139-150. (PMID: 29621954) Exp Cell Res. 1999 Nov 25;253(1):230-8. (PMID: 10579925) Oncol Rep. 2010 Nov;24(5):1363-9. (PMID: 20878132) Cell. 1995 Jan 27;80(2):269-78. (PMID: 7834746) PLoS One. 2018 Nov 8;13(11):e0207310. (PMID: 30408112) Biochim Biophys Acta. 2012 Nov-Dec;1819(11-12):1142-53. (PMID: 22989952) J Natl Cancer Inst. 2008 Nov 19;100(22):1630-42. (PMID: 19001604) Annu Rev Pharmacol Toxicol. 2010;50:157-86. (PMID: 20055701) Oncol Rep. 2017 Jul;38(1):352-358. (PMID: 28560431) J Gynecol Oncol. 2010 Dec 30;21(4):248-54. (PMID: 21278887) J Cell Biol. 2002 Jul 22;158(2):227-33. (PMID: 12119361) Fertil Steril. 2011 May;95(6):2107-13, 2113.e1-4. (PMID: 21411082) Biol Reprod. 1999 Jul;61(1):195-9. (PMID: 10377049) Best Pract Res Clin Obstet Gynaecol. 2017 May;41:3-14. (PMID: 27743768) Trends Biochem Sci. 2012 Nov;37(11):460-5. (PMID: 22944280) |
| فهرسة مساهمة: | Keywords: cancer; lysophosphatidic acid; lysophosphatidic acid receptor; microRNA; molecular mechanism |
| تواريخ الأحداث: | Date Created: 20220711 Latest Revision: 20220716 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC9259992 |
| DOI: | 10.3389/fonc.2022.917471 |
| PMID: | 35814375 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2234-943X |
|---|---|
| DOI: | 10.3389/fonc.2022.917471 |